New Paradigm Molecular Pathology: Early-Stage Non-Small Cell Lung Cancer (NSCLC) Biomarker-Informed Treatment and Longitudinal Minimal Residual Disease (MRD) Monitoring
Wednesday, November 15, 2023
9:00 AM – 9:50 AM MST
Recent studies indicate that biomarker-informed adjuvant therapy selection in early-stage NSCLC can extend disease-free survival. Genotype may indicate a benefit from targeted therapy; however, PD-L1 expression can be a negative predictive factor (e.g. EGFR+ NSCLC treated with a Tyrosine Kinase Inhibitor (TKI). Considering both stage and mutation/PD-L1 status is critical when choosing between targeted therapy, chemotherapy, or immunotherapy for adjuvant treatment. Real-world survival data indicates poor prognosis in patients with locoregional recurrence. There is a need for new diagnostic tools to detect molecular recurrence through minimal residual disease (MRD) monitoring, enabling earlier and potentially more efficacious treatment for NSCLC.